3 September 2018 Blog Post: New Research in August on "Baby" Aspirin
When considering all cardiovascular events combined, a daily aspirin showed no significant effect. The primary endpoint occurred in 269 (4.29%) individuals in the aspirin group versus 281 (4.48%) in the placebo group.
Of interest, aspirin did reduce the risk of total and nonfatal heart attacks. Aspirin accounted for an 82.1% reduction in these events for those aged 50-59 years of age and and a 54.3% reduction in the 59-69 age group. There was no effect of aspirin use on risk of stroke.
Bleeding was relatively infrequent, and when it occurred, was mild and most commonly from the GI tract – 61 (0.97%) individuals in the aspirin group versus 29 (0.46%) in the placebo group. Other commonly reported side effects of aspirin were indigestion, nosebleeds, gastroesophageal reflux disease, and upper abdominal pain.
So it looks as if I will need to amend my “desert island” advice to exclude any risk reduction in stroke. And 1% of you may get a GI or nose bleed falling out of the coconut tree…
In an equally fascinating study published earlier in the month, Canadian researchers suggested that a low dose daily aspirin could reduce HIV susceptibility. So the aspirin story continues on – a century after becoming available.
𝗦𝗶𝗴𝗻 𝗨𝗽 𝗳𝗼𝗿 𝗢𝘂𝗿 𝗡𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿
Dig deeper into the health topics you care about most by signing up for our newsletter.
by submitting this form you indicate you have
of Use. Please contact us to for us for more